Table 2 Anti-TNF treatment history
UC (n = 35) | CD (n = 252) | |
|---|---|---|
First-line anti-TNF therapy, n (%) | ||
Infliximab | 35 (100) | 252 (100) |
Treatment period, months, median (IQR) | 5.8 (1.4, 8.8) | 12.8 (7.6, 33.9) |
Second anti-TNF therapy, n (%) | 1 (2.9) | 10 (4.0) |
Adalimumab, n/N (%) | 1/1 (100) | 1/10 (10) |
Treatment period, months, median | 3.9 (3.9, 3.9) | 5.0 (5.0, 5.0) |
(IQR) | ||
Infliximab, n/N (%) | 0 | 9/10 (90) |
Treatment period, months, median (IQR) | – | 11.2 (7.1, 17.6) |